This study is a Phase 3, multi-center, randomized, 6-week, double-blind, placebo-controlled, parallel-group trial to assess the efficacy and safety of solriamfetol in adolescents aged 12 to <18 years with ADHD.
Inclusion Criteria:
Exclusion Criteria:
akim@axsome.com929-618-4421
Up to 6 weeks
Up to 6 weeks
Up to weeks
A Study to Assess the Efficacy and Safety of Solriamfetol in Children With ADHD
A Study to Assess the Efficacy and Safety of Solriamfetol in Subjects With ADHD (FOCUS)
A Controlled Study of Solriamfetol for Attention Deficit Hyperactivity Disorder (ADHD) in Adults
Progressing TAAR-1, Dopamine, and Norepinephrine in Depression Using Solriamfetol
A Trial of Solriamfetol in the Treatment of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome
Clinical Assessment of Response in the Treatment of Depression With Daytime Sleepiness Using Solriamfetol
Safety and Efficacy of ADDERALL XR in the Treatment of Adolescents Aged 13-17 With Attention Deficit Hyperactivity Disorder (ADHD)
Studying Solriamfetol Modulation of TAAR-1, Dopamine, and Norepinephrine in Shift Work Disorder (SUSTAIN)